Carlos Perez, MD
Psychiatry · Dalton, GANPI 1033229661
Payments from drug & device makers
Across 453 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$645
- Alkermes, Inc.$622
- Johnson & Johnson$578
- plus $3K from 18 others
What the payments were for
- Food & beverage$8,868100%
- Education$370%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 76 | $1,564 |
| Neurocrine Biosciences, Inc. | 59 | $1,416 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 66 | $1,080 |
| Teva Pharmaceuticals USA, Inc. | 39 | $645 |
| Alkermes, Inc. | 29 | $622 |
| Johnson & Johnson | 22 | $578 |
| AbbVie(2 entities) | 36 | $576 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $481 |
| Axsome Therapeutics, Inc. | 7 | $383 |
| Lundbeck LLC | 18 | $348 |
| Almatica Pharma LLC | 23 | $314 |
| Avanir Pharmaceuticals, Inc. | 16 | $239 |
| Vanda Pharmaceuticals Inc. | 11 | $186 |
| Supernus Pharmaceuticals, Inc. | 4 | $87 |
| Abbott | 3 | $62 |
| Corium, LLC | 2 | $58 |
| Sunovion Pharmaceuticals Inc. | 3 | $56 |
| E.r. Squibb & Sons, L.L.C. | 2 | $50 |
| AstraZeneca | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| Eisai Inc. | 2 | $27 |
| GSK | 1 | $23 |
| Bausch Health US, LLC | 1 | $16 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$592
- Auvelity$239
- REXULTI$225
- INVEGA SUSTENNA$140
- CAPLYTA$124
- ABILIFY ASIMTUFII$122
- ABILIFY MAINTENA$122
- VRAYLAR$103
How this compares
$8,905 in reported general payments places this provider in the 85th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 45 | $390,358 |
| IngrezzaValbenazine Tosylate | 35 | $289,963 |
| RexultiBrexpiprazole | 139 | $240,385 |
| VraylarCariprazine Hcl | 124 | $208,648 |
| AustedoDeutetrabenazine | 20 | $114,862 |
| TrintellixVortioxetine Hydrobromide | 121 | $85,900 |
| BelsomraSuvorexant | 120 | $58,776 |
| LybalviOlanzapine/Samidorphan Malate | 27 | $51,626 |
| CaplytaLumateperone Tosylate | 29 | $48,110 |
| Abilify MaintenaAripiprazole | 12 | $34,016 |
| AuvelityDextromethorphan Hbr/Bupropion | 29 | $27,923 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $14,543 |
| Lurasidone Hcl | 107 | $12,827 |
| Aripiprazole | 258 | $8,647 |
| Ziprasidone Hcl | 83 | $7,506 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $645 | $505,22065 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,416 | $289,96335 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,564 | $274,401151 claims |
| AbbVieVraylar | $576 | $208,648124 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $481 | $85,900121 claims |
| MerckBelsomra | $15 | $58,776120 claims |
| Alkermes, Inc.Lybalvi | $622 | $51,62627 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,080 | $48,11029 claims |
| Axsome Therapeutics, Inc.Auvelity | $383 | $27,92329 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $239 | $14,54312 claims |
| Almatica Pharma LLCSertraline Hcl | $314 | $3,251486 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Dalton
- Robert RiesenbergAtlanta$51.1M
- Saundra Maass-RobinsonAtlanta$11.1M
- David PurselleAtlanta$7.4M
- Maria JohnsonDecatur$5.4M
- Bethany DavisAtlanta$4.4M
- Michael BanovMarietta$4.2M
- Michael MobleySavannah$2.9M
- Richard PettyLoganville$2.9M
- Felipe SuplicyRome$2.3M
- Angelo SambunarisAlpharetta$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.